Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.
about
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewDysregulation of ubiquitin ligases in cancerUltraconserved long non-coding RNA uc.63 in breast cancerp53 Family and Cellular Stress Responses in Cancer.Targeting RING domains of Mdm2-MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cellsDownregulation of RNF128 Predicts Progression and Poor Prognosis in Patients with Urothelial Carcinoma of the Upper Tract and Urinary Bladder.Spatiotemporal progression of ubiquitin-proteasome system inhibition after status epilepticus suggests protective adaptation against hippocampal injury.Therapeutic opportunities within the DNA damage response.Design Principles Involving Protein Disorder Facilitate Specific Substrate Selection and Degradation by the Ubiquitin-Proteasome System.Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma.Regulation of transcriptional activators by DNA-binding domain ubiquitination.Paving the way to targeting HECT ubiquitin ligases.Targeted Protein Degradation by Small Molecules.miRNA-140-5p: new avenue for pulmonary arterial hypertension drug development?p73 promotes glioblastoma cell invasion by directly activating POSTN (periostin) expression.A General Strategy for Discovery of Inhibitors and Activators of RING and U-box E3 Ligases with Ubiquitin Variants.Breast cancer metastasis suppressor OTUD1 deubiquitinates SMAD7.Ubiquitin ligases in oncogenic transformation and cancer therapy.Ubiquitin Specific Peptidase 15 (USP15) suppresses glioblastoma cell growth via stabilization of HECTD1 E3 ligase attenuating WNT pathway activity.Ubiquitin-Dependent Regulation of the Mammalian Hippo Pathway: Therapeutic Implications for Cancer.TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis.A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology
P2860
Q27304386-8A188238-F172-498D-865B-8E60CF697A5BQ28086796-13002E25-0032-4B9A-8DF3-31FF65ABA90FQ33829275-C3617E3E-912D-4405-9E64-61A98D1B8029Q34377287-C89A15A2-4E27-40E4-A982-26D13D913053Q36485161-65213EAD-99D0-4EE0-923D-66E22EF5380AQ37514045-8B99A386-99F4-4338-958E-FB7A58EABC1DQ37663375-29C03003-9E8B-46A5-B2E5-25D171B60B09Q38364665-A5C35FF5-15D6-49F4-A13B-E60CD9DAA071Q38724758-6236F520-981C-40E1-A29D-C55EE0DB65F5Q38776967-3EC5FFE8-0567-4E3F-B8ED-099C9FF9ACD1Q38864889-94D29EF7-FED7-40CD-9058-B48F20555155Q38948973-C26644B7-0FEE-4403-B490-463736AFC801Q38978952-140C590B-AFEC-4476-856F-E0B14BDE181EQ40549879-0B3544B9-B08B-4C04-A49E-88408B5A8BA8Q41842526-BF771482-A50C-4E9C-A265-FA72CFFAB1DAQ42635927-2AD2604D-48E9-436C-8822-1786A2282279Q45972509-BC257412-10CF-4A7D-9B16-A2BA641E39ABQ46609299-AF2F7D56-F66E-445E-8718-FFBB73042D97Q47104172-9D343191-F616-4F2D-B130-72FD68C75A77Q54973587-3C71E3A2-D7A8-4753-9A0F-2A6B18BC4325Q54979954-29E2B6EF-BB43-41C0-8147-1A64A568CA56Q54989340-9C9EDEB4-ABA8-43FD-B8A3-680DDDE07856
P2860
Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.
@en
type
label
Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.
@en
prefLabel
Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.
@en
P2093
P2860
P921
P356
P1433
P1476
Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.
@en
P2093
Barak Rotblat
Gerry Melino
Vivien Landré
P2860
P304
P356
10.18632/ONCOTARGET.2431
P407
P577
2014-09-01T00:00:00Z
2014-09-30T00:00:00Z